NUTX
Nutex Health Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Strong buy
+78/100
Last price
218.40
▼ 6.60 (2.93%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
225.00
Day high
226.00
Day low
217.46
Volume
122.78K
Market cap
$1.50B
P/E (TTM)
8.65
52W range
83.99 – 226.00
Trailing performance
Returnvs SPY
1W
+3.95%
+2.0%
1M
+13.02%
+11.9%
3M
+21.64%
+17.1%
6M
+112.24%
+94.1%
YTD
+32.67%
+18.4%
1Y
+102.45%
+86.0%
3Y
+617.24%
+535.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
15 more panels on NUTX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
2.00M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 31, 26 | JAUMOT FRANK E Director |
— | 603 | — | Direct |
| Jul 31, 26 | GRENAS CHERYL YVONNE Director |
— | 603 | — | Direct |
| Jul 31, 26 | REED MICHAEL LEE Director |
— | 603 | — | Indirect |
| Jul 31, 26 | SAUNDERS SCOTT J. Director |
— | 603 | — | Direct |
| Mar 20, 26 | JAUMOT FRANK E Director |
BUY | 150 | $14.03K | Direct |
| Mar 19, 26 | HOSSEINION WARREN President |
BUY | 252 | $23.71K | Direct |
| Mar 17, 26 | SPEARS KELVIN Director |
BUY | 10 | $945 | Direct |
| Mar 16, 26 | MONTGOMERY PAMELA W. Officer |
— | 1.52K | — | Direct |
| Mar 13, 26 | MONTGOMERY PAMELA W. Officer |
BUY | 79 | $7.02K | Direct |
| Mar 10, 26 | HOSSEINION WARREN President |
— | 6.29K | — | Direct |
| Mar 10, 26 | HOSSEINION WARREN President |
CONVERSION | 3.66K | $353.83K | Direct |
| Mar 10, 26 | LUQMAN ELISA V Officer |
— | 2.08K | — | Indirect |
| Mar 10, 26 | CHANG MICHAEL L Officer |
— | 2.08K | — | Indirect |
| Mar 10, 26 | VO THOMAS T Chief Executive Officer |
— | 8.33K | — | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BATES JON CHRISTIAN |
Chief Financial Officer | 8.30K | Conversion of Exercise of derivative security |
CHANG MICHAEL L |
Officer | — | Conversion of Exercise of derivative security |
DETILLIO JOSHUA |
Chief Operating Officer | 6.48K | Conversion of Exercise of derivative security |
GRENAS CHERYL YVONNE |
Director | 670 | Conversion of Exercise of derivative security |
HOSSEINION WARREN |
President | 7.76K | Purchase |
JAUMOT FRANK E |
Director | 753 | Conversion of Exercise of derivative security |
LUQMAN ELISA V |
Officer | — | Conversion of Exercise of derivative security |
MONTGOMERY PAMELA W. |
Officer | 2.76K | Conversion of Exercise of derivative security |
SPEARS KELVIN |
Director | 32.14K | Purchase |
VO THOMAS T |
Chief Executive Officer | — | Conversion of Exercise of derivative security |
Fundamentals
Market cap$1.50B
Enterprise value$1.75B
Revenue (TTM)$846.72M
Gross profit$461.53M
EBITDA$502.27M
Net income$179.92M
EPS (TTM)$25.24
Free cash flow$130.75M
Total cash$205.21M
Total debt$347.34M
Book value / share$57.62
Shares outstanding6.85M
Float4.15M
Short % of float28.56%
Dividend yield0.00%
Beta (5Y)2.00
Valuation & profitability ratios
Trailing P/E8.65
Forward P/E10.74
PEG ratio—
Price / sales—
Price / book3.79
EV / revenue2.07
EV / EBITDA3.49
Gross margin54.51%
Operating margin57.75%
Profit margin21.25%
Return on equity64.56%
Return on assets33.32%
Debt / equity68.47
Current ratio5.00
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $875.26M | $479.95M | $247.65M | $219.29M | +82.4% |
| Operating revenue | $875.26M | $479.95M | $247.65M | $219.29M | +82.4% |
| Cost of revenue | $430.98M | $283.69M | $212.87M | $203.87M | +51.9% |
| Gross profit | $444.28M | $196.26M | $34.77M | $15.42M | +126.4% |
| Selling, general & admin | $168.66M | $58.48M | $36.07M | $20.00M | +188.4% |
| Total operating expense | $168.66M | $58.48M | $36.28M | $20.00M | +188.4% |
| Operating income | $275.63M | $137.78M | -$1.51M | -$4.58M | +100.0% |
| Net interest income | -$22.23M | -$19.93M | -$16.32M | -$12.49M | -11.5% |
| Pre-tax income | $244.78M | $109.83M | -$48.49M | -$419.65M | +122.9% |
| Tax provision | $64.42M | $15.02M | -$5.07M | $13.09M | +328.9% |
| Net income | $70.79M | $52.10M | -$45.79M | -$424.78M | +35.9% |
| Net income to common | $70.79M | $52.10M | -$45.79M | -$424.78M | +35.9% |
| Basic EPS | 11.13 | 10.25 | -10.50 | -100.50 | +8.6% |
| Diluted EPS | 10.48 | 9.71 | -10.50 | -100.50 | +7.9% |
| EBIT | $267.01M | $129.76M | -$32.17M | -$407.16M | +105.8% |
| EBITDA | $287.54M | $148.73M | -$14.58M | -$394.03M | +93.3% |
| Basic shares | 6.36M | 5.09M | 4.36M | 4.23M | +25.0% |
| Diluted shares | 6.76M | 5.37M | 4.36M | 4.23M | +25.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $185.57M | $40.64M | $22.00M | $34.26M | +356.6% |
| Cash & short-term investments | $185.57M | $40.64M | $22.00M | $34.26M | +356.6% |
| Accounts receivable | $325.42M | $236.05M | $62.78M | $58.32M | +37.9% |
| Inventory | $2.87M | $2.85M | $3.39M | $3.53M | +0.6% |
| Total current assets | $538.81M | $292.48M | $90.85M | $97.97M | +84.2% |
| Property, plant & equipment | $343.90M | $324.69M | $269.39M | $295.15M | +5.9% |
| Goodwill & intangibles | $35.15M | $29.45M | $37.58M | $38.20M | +19.4% |
| Total assets | $918.52M | $655.32M | $398.25M | $431.75M | +40.2% |
| Total current liabilities | $157.91M | $154.22M | $58.31M | $54.86M | +2.4% |
| Current debt | $14.08M | $17.95M | $14.18M | $15.17M | -21.6% |
| Long-term debt | $29.17M | $22.47M | $26.31M | $23.05M | +29.9% |
| Total debt | $351.39M | $340.30M | $275.76M | $267.20M | +3.3% |
| Total liabilities | $495.09M | $466.79M | $319.14M | $311.42M | +6.1% |
| Retained earnings | -$286.19M | -$356.98M | -$409.07M | -$363.29M | +19.8% |
| Shareholder equity | $329.45M | $132.44M | $61.45M | $95.86M | +148.8% |
| Working capital | $380.90M | $138.25M | $32.54M | $43.11M | +175.5% |
| Net tangible assets | $294.30M | $102.99M | $23.87M | $57.66M | +185.8% |
| Shares issued | 7.09M | 5.51M | 4.51M | 4.33M | +28.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $180.36M | $94.81M | -$43.42M | -$432.74M | +90.2% |
| Depreciation & amortisation | $20.53M | $18.97M | $17.59M | $13.13M | +8.2% |
| Stock-based compensation | $117.00M | $16.55M | $2.84M | $189.58K | +606.8% |
| Change in working capital | -$87.74M | -$104.23M | -$1.53M | $64.32M | +15.8% |
| Operating cash flow | $248.13M | $23.15M | $1.26M | $50.61M | +971.7% |
| Capital expenditure | -$2.53M | -$2.30M | -$9.50M | -$14.63M | -9.6% |
| Investing cash flow | -$5.24M | -$5.61M | -$11.24M | -$4.34M | +6.5% |
| Share buybacks | -$5.00M | $0 | $0 | — | — |
| Dividends paid | -$74.28M | -$6.44M | -$5.21M | -$51.23M | -1,053.7% |
| Financing cash flow | -$97.95M | $1.09M | -$2.27M | -$48.13M | -9,077.9% |
| Free cash flow | $245.60M | $20.85M | -$8.24M | $35.97M | +1,078.0% |
| End cash position | $185.87M | $40.64M | $22.00M | $34.26M | +357.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $210.75M | $216.49M | $151.68M | $267.80M | $243.99M | — | -2.6% |
| Operating revenue | $210.75M | $216.49M | $151.68M | $267.80M | $243.99M | — | -2.6% |
| Cost of revenue | $69.47M | $124.75M | $105.54M | $112.92M | $119.06M | — | -44.3% |
| Gross profit | $141.28M | $91.73M | $46.14M | $154.88M | $124.92M | — | +54.0% |
| Selling, general & admin | $19.56M | $10.46M | $15.22M | $24.51M | $91.25M | — | +86.9% |
| Total operating expense | $19.56M | $10.46M | $15.22M | $24.51M | $91.25M | — | +86.9% |
| Operating income | $121.72M | $81.27M | $30.92M | $130.37M | $33.68M | — | +49.8% |
| Net interest income | -$4.67M | -$4.68M | -$4.98M | -$5.45M | -$5.68M | — | +0.2% |
| Pre-tax income | $117.08M | $76.56M | $25.89M | $123.94M | $23.73M | — | +52.9% |
| Tax provision | $20.77M | $13.80M | $9.29M | $27.14M | $7.59M | — | +50.5% |
| Net income | $65.84M | $46.81M | $11.83M | $55.44M | -$17.70M | — | +40.7% |
| Net income to common | $65.84M | $46.81M | $11.83M | $55.44M | -$17.70M | — | +40.7% |
| Basic EPS | 9.58 | 6.70 | — | 8.27 | -2.95 | 3.74 | +43.0% |
| Diluted EPS | 9.38 | 6.52 | — | 7.76 | -2.95 | 3.33 | +43.9% |
| EBIT | $121.76M | $81.24M | $30.87M | $129.39M | $29.41M | — | +49.9% |
| EBITDA | $127.07M | $86.73M | $36.06M | $134.39M | $34.66M | — | +46.5% |
| Basic shares | 6.87M | 6.99M | — | 6.70M | 6.00M | 5.67M | -1.6% |
| Diluted shares | 7.02M | 7.18M | — | 7.14M | 6.00M | 6.37M | -2.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $205.21M | $207.35M | $185.57M | $166.05M | $96.73M | -1.0% |
| Cash & short-term investments | $205.21M | $207.35M | $185.57M | $166.05M | $96.73M | -1.0% |
| Accounts receivable | $356.70M | $345.90M | $325.42M | $394.76M | $354.96M | +3.1% |
| Inventory | $4.21M | $4.68M | $2.87M | $3.16M | $2.27M | -10.1% |
| Total current assets | $585.65M | $579.65M | $538.81M | $592.65M | $473.02M | +1.0% |
| Property, plant & equipment | $340.92M | $342.18M | $343.90M | $335.89M | $326.06M | -0.4% |
| Goodwill & intangibles | $34.50M | $34.82M | $35.15M | $35.47M | $28.80M | -0.9% |
| Total assets | $964.63M | $957.32M | $918.52M | $964.52M | $841.03M | +0.8% |
| Total current liabilities | $117.22M | $184.44M | $157.91M | $185.46M | $194.87M | -36.4% |
| Current debt | $8.59M | $16.87M | $14.08M | $23.31M | $26.81M | -49.1% |
| Long-term debt | $31.11M | $24.26M | $29.17M | $25.57M | $20.46M | +28.2% |
| Total debt | $347.34M | $349.09M | $351.39M | $358.60M | $345.25M | -0.5% |
| Total liabilities | $457.32M | $515.26M | $495.09M | $526.49M | $504.15M | -11.2% |
| Retained earnings | -$173.54M | -$239.38M | -$286.19M | -$298.02M | -$353.46M | +27.5% |
| Shareholder equity | $394.32M | $346.29M | $329.45M | $317.17M | $235.25M | +13.9% |
| Working capital | $468.43M | $395.21M | $380.90M | $407.19M | $278.15M | +18.5% |
| Net tangible assets | $359.82M | $311.47M | $294.30M | $281.69M | $206.45M | +15.5% |
| Shares issued | 6.84M | 6.95M | 7.09M | 6.91M | 6.60M | -1.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $96.32M | $62.76M | $16.61M | $96.80M | $16.14M | — | +53.5% |
| Depreciation & amortisation | $5.32M | $5.49M | $5.19M | $5.00M | $5.25M | — | -3.2% |
| Stock-based compensation | $2.88M | -$3.92M | -$2.60M | $13.22M | $78.75M | — | +173.7% |
| Change in working capital | -$20.72M | $12.08M | $56.92M | -$43.56M | -$70.77M | — | -271.5% |
| Operating cash flow | $34.20M | $75.52M | $70.39M | $99.51M | $27.26M | — | -54.7% |
| Capital expenditure | -$2.54M | -$1.20M | -$1.41M | -$302.00K | -$751.00K | — | -111.5% |
| Investing cash flow | -$2.54M | -$1.20M | -$5.07M | -$302.00K | $196.00K | — | -111.5% |
| Share buybacks | — | -$31.73M | — | — | — | $0 | — |
| Dividends paid | -$13.26M | -$15.36M | -$32.10M | -$23.40M | -$11.41M | — | +13.6% |
| Financing cash flow | -$35.19M | -$49.55M | -$45.79M | -$29.90M | -$15.45M | — | +29.0% |
| Free cash flow | $31.66M | $74.32M | $68.98M | $99.21M | $26.51M | — | -57.4% |
| End cash position | $207.11M | $207.35M | $185.87M | $166.05M | $96.73M | — | -0.1% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 4.95 | 9.38 | +89.3% |
| Mar 2026 | 5.56 | 5.74 | +3.3% |
| Dec 2025 | 5.56 | 1.62 | -70.8% |
| Sep 2025 | 1.95 | 7.76 | +298.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 5.71 | 5 | $214.98M | -19.7% |
| Next quarter | 6.21 | 5 | $229.78M | +51.5% |
| Current year | 27.79 | 5 | $872.02M | -0.4% |
| Next year | 27.87 | 5 | $964.20M | +10.6% |
Analyst targets & ownership
Mean target$288.20
High target$325.00
Low target$200.00
Implied upside31.96%
Analyst count5
ConsensusSTRONG BUY
Strong buy / Buy1 / 4
Hold0
Sell / Strong sell0 / 0
Held by insiders29.23%
Held by institutions43.95%
Institutions holding226
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
213.33
+2.38% from price
SMA 20
210.47
+3.77% from price
SMA 50
190.67
+14.55% from price
SMA 100
170.47
+28.12% from price
SMA 200
147.71
+47.85% from price
EMA 12
213.52
+2.28% from price
EMA 26
206.18
+5.93% from price
EMA 50
194.42
+12.33% from price
RSI (14)
59.0
Neutral
MACD (12,26,9)
7.34
Hist 0.02
ATR (14)
10.19
4.67% of price
Realised vol 30D
47.4%
Annualised
Bollinger upper
226.21
20, 2σ
Bollinger lower
194.74
20, 2σ
50 / 200 cross
Golden
190.67 vs 147.71
Trend bias
Above 200
+47.85%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.97
More volatile than market
Correlation to SPY
0.28
Largely independent
Realised vol 30D
47.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-54.3%
Peak to trough
Max drawdown 5Y
-99.9%
Peak to trough
ATR 14
10.19
4.67% of price
Beta (reported)
2.00
5Y monthly, from filing
Short interest
Shares short
1.23M
Prior 1.13M
Change vs prior
+9.2%
Shorts adding
% of float
28.56%
Heavily shorted
% of shares out
18.02%
Against total outstanding
Days to cover
8.2
Crowded exit
Float
4.15M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 25, 26 | Freedom Capital Markets | MAINTAINED | Buy | Buy |
| Sep 4, 26 | B. Riley Securities | MAINTAINED | Buy | Buy |
| Aug 11, 26 | Lake Street | MAINTAINED | Buy | Buy |
| Jun 26, 26 | B. Riley Securities | INITIATED | — | Buy |
| Jun 2, 26 | Lake Street | INITIATED | — | Buy |
| Aug 26, 25 | Maxim Group | MAINTAINED | Buy | Buy |
| Jul 10, 25 | Benchmark | MAINTAINED | Buy | Buy |
| May 20, 25 | Maxim Group | MAINTAINED | Buy | Buy |
| May 15, 25 | Benchmark | MAINTAINED | Buy | Buy |
| Apr 9, 25 | Benchmark | MAINTAINED | Buy | Buy |
| Apr 8, 25 | Maxim Group | MAINTAINED | Buy | Buy |
| Feb 13, 25 | Maxim Group | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateNov 1, 2019
Last split1:10
Split dateJul 3, 2024
SEC filings
Trading Registrations
8-A12B · 2026-09-22
Corporate Changes & Voting Matters
8-K · 2026-09-11
Corporate Changes & Voting Matters
8-K · 2026-08-31
Corporate Changes & Voting Matters
8-K · 2026-08-24
Corporate Changes & Voting Matters
8-K · 2026-08-13
Periodic Financial Reports
10-Q · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-07-21
Corporate Changes & Voting Matters
8-K · 2026-04-30
Headlines
5 Stocks With Recent Price Strength After a Mixed September
Zacks · 2d ago
Bet on These 4 Stocks With Strong Net Profit Margins to Boost Returns
Zacks · 6d ago
Here's What Could Help Nutex Health (NUTX) Maintain Its Recent Price Strength
Zacks · 9d ago
Can Nutex Health (NUTX) Stay Undervalued As Earnings Shift?
Simply Wall St. · 13d ago
Nutex Health (NUTX) Could Be 29% Undervalued As Nasdaq Texas Listing Nears
Simply Wall St. · 13d ago
Nutex Health Receives Approval to List on Nasdaq in Texas, New York
MT Newswires · 14d ago
Nutex Health Approved for Dual Listing on Nasdaq Texas
PR Newswire · 14d ago
Zacks.com featured highlights EuroDry, Vince Holding, Nutex, TXO Partners and KB Financial
Zacks · 19d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.